TGA Provides Regulatory Clearance for LTR Pharma’s SPONTANĀ® Phase II Clinical Study
By API User
10 December 2025 – Brisbane, Australia | LTR Pharma Limited (ASX:LTP) has today announced that it has received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) to commence its clinical trial activities for a Phase II clinical study for its nasal erectile dysfunction treatment SPONTAN®. This follows confirmation and acceptance of the Company’s Clinical Trial Notification … Continued